Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19PRNewsWire • 10/09/20
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.PRNewsWire • 10/01/20
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteomePRNewsWire • 09/07/20
Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trialsPRNewsWire • 07/28/20
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 millionPRNewsWire • 07/20/20
Grifols (GRFS) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 03/05/20
This Pharma Stock Dodged A Broad Slide For Drugmakers — Here's WhyInvestors Business Daily • 07/05/19